Skip to main content

NCT02257736 - A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistan

A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)


CSR Summary

N/A


Data Specification

Available upon data access


Annotated CRF

Available upon data access

Product Info

Generic Name
Apalutamide
Product Name
ERLEADA®
Therapeutic Area
Cancers and Other Neoplasms
Enrollment
982
% Female
0.0%
% White
75.2%
Product Class
Nonsteroidal antiandrogen 
Sponsor Protocol Number
56021927PCR3001
Data Partner
Johnson & Johnson
Condition Studied
Neoplasms, Prostatic
Mean/Median Age (Years)
71.1

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.